Journal of Enzyme Inhibition and Medicinal Chemistry (Jan 2019)

Dual-target anti-Alzheimer’s disease agents with both iron ion chelating and monoamine oxidase-B inhibitory activity

  • Zhisheng Mi,
  • Bing Gan,
  • Sihang Yu,
  • Jianan Guo,
  • Changjun Zhang,
  • Xiaoying Jiang,
  • Tao Zhou,
  • Jing Su,
  • Renren Bai,
  • Yuanyuan Xie

DOI
https://doi.org/10.1080/14756366.2019.1634703
Journal volume & issue
Vol. 34, no. 1
pp. 1489 – 1497

Abstract

Read online

MAO-B leads to an increase in the levels of hydrogen peroxide and oxidative free radicals, which contribute to the aetiology of the AD. Thus, both iron ion chelators and MAO-B inhibitors can be used to treat AD. Taking the coumarin derivatives and hydroxypyridinones as the lead compounds, a series of dual-target hybrids were designed and synthesised by Click Chemistry. The compounds were biologically evaluated for their iron ion chelating and MAO-B inhibitory activity. Most of the compounds displayed excellent iron ion chelating activity and moderate to good anti-MAO-B activity. Compounds 27b and 27j exhibited the most potent MAO-B inhibitory activity, with IC50 values of 0.68 and 0.86 μM, respectively. In summary, these dual-target compounds have the potential anti-AD activity.

Keywords